Comparing Semler Scientific (NASDAQ:SMLR) & Xcorporeal (OTCMKTS:XCRP)

Semler Scientific (NASDAQ:SMLR) and Xcorporeal (OTCMKTS:XCRP) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation & Earnings

This table compares Semler Scientific and Xcorporeal”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Semler Scientific	$61.74 million	2.97	$20.58 million	$2.79	9.29
Xcorporeal	N/A	N/A	N/A	N/A	N/A

Semler Scientific has higher revenue and earnings than Xcorporeal.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Semler Scientific and Xcorporeal, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Semler Scientific	0	0	0	1	4.00
Xcorporeal	0	0	0	0	N/A

Institutional & Insider Ownership

49.4% of Semler Scientific shares are owned by institutional investors. 13.0% of Semler Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Semler Scientific and Xcorporeal’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Semler Scientific	25.62%	21.17%	19.40%
Xcorporeal	N/A	N/A	N/A

Summary

Semler Scientific beats Xcorporeal on 7 of the 7 factors compared between the two stocks.

About Semler Scientific

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.